Aaron Mulhall is a Respiratory physician. OpenAlex indexes 21 publications with 324 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4700 Bayou Blvd Ste 6
Pensacola, FL 325031901
Telephone
850-477-9253Provider last certified this registry record 11 Mar 2026.
Industry payments
34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insmed, Inc.Program year20259 payments
- GENZYME CORPORATIONProgram year20253 payments
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
70.3%Corticosteroid37.1%Breztri Aerosphere36%Trelegy Ellipta28%Budesonide-Formoterol Fumarate13%Fluticasone Propionate11%Arnuity Ellipta7%Fluticasone Propionate Hfa6%Part D<11 patientsbeta2-Adrenergic Agonist15.2%Albuterol Sulfate Hfa83%Striverdi Respimat17%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
11.8%Corticosteroid11.8%Prednisone100%Part D≥39 patientsAnti-infectives
10.3%Macrolide Antimicrobial7.6%Azithromycin100%Part D≥15 patientsPenicillins with extended spectrum2.7%Amoxicillin-Clavulanate Potass100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs
Expert Opinion on Investigational Drugs
2016 - Bilateral Diaphragmatic Paralysis: A Rare Complication Related to Endoscopic Ultrasound–Guided Celiac Plexus Neurolysis
Annals of the American Thoracic Society
2016 - Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs
Expert Opinion on Investigational Drugs
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”